Edition:
India

Biocon Ltd (BION.NS)

BION.NS on National Stock Exchange of India

629.65INR
22 Jun 2018
Change (% chg)

Rs9.30 (+1.50%)
Prev Close
Rs620.35
Open
Rs619.90
Day's High
Rs633.80
Day's Low
Rs615.25
Volume
2,051,466
Avg. Vol
2,619,270
52-wk High
Rs696.60
52-wk Low
Rs316.25

Select another date:

Tue, Jun 5 2018

BUZZ-India's Biocon hits record high after FDA approves partner's drug

** Shares of Biocon Ltd rise as much as 6.4 pct to record high of 696.60 rupees

BUZZ-India's Biocon falls; plant gets observations from US FDA, European regulator

** Biopharmaceutical company Biocon Ltd's shares fall as much as 5.1 pct to 630 rupees, its biggest daily pct loss since Feb. 6

BRIEF-India's Biocon Says USFDA, European Regulator Issue Observations On Bangalore Plant

* SAYS US-FDA COMPLETED PRE-APPROVAL INSPECTION OF STERILE DRUG PRODUCT PLANT IN BANGALORE AND ISSUED A FORM 483 WITH 7 OBSERVATIONS

BRIEF-Biocon Q4 Net Profit Up 2 Percent

* Q4 NET PROFIT UP 2 PERCENT TO 1.30 BILLION RUPEES; Q4 TOTAL REVENUE 12.37 BILLION RUPEES VERSUS 9.74 BILLION RUPEES YEAR-AGO Further company coverage: (Reuters.Briefs@thomsonreuters.com)

Biocon fourth-quarter profit rises 2.2 percent

Biocon Ltd, India's biggest biotechnology company, posted a marginal 2.2 percent rise in net profit on Thursday.

India's Biocon Q4 profit rises 2.2 pct

April 26 Biocon Ltd, India's biggest biotechnology company, posted a marginal 2.2 percent rise in net profit on Thursday.

BRIEF-Mylan, Biocon Seek To Accelerate Introduction Of Adalimumab Biosimilar In EU

* MYLAN, BIOCON SEEK TO ACCELERATE INTRODUCTION OF ADALIMUMAB BIOSIMILAR IN EU Source text - https://bit.ly/2IIPzM6 Further company coverage:

BRIEF-Mylan, Biocon get approvals from European Commission, TGA Australia for Semglee, Biosimilar Insulin Glargine

* MYLAN AND BIOCON RECEIVE APPROVALS FROM THE EUROPEAN COMMISSION AND TGA AUSTRALIA FOR SEMGLEE™, BIOSIMILAR INSULIN GLARGINE Source text for Eikon: Further company coverage:

BRIEF-India's Biocon ‍Says U.S. FDA Completed Pre-Approval Inspection At Malaysia Unit ​

* ‍U.S. FDA COMPLETED PRE-APPROVAL INSPECTION AT MALAYSIA FACILITY AND ISSUED FORM 483 WITH 6 OBSERVATIONS​ Source text - http://bit.ly/2EUL56I Further company coverage:

BRIEF-Cytosorbents Expands Its Partnership With Biocon To Launch Cytosorb In Malaysia

* CYTOSORBENTS EXPANDS ITS PARTNERSHIP WITH BIOCON TO LAUNCH CYTOSORB® IN MALAYSIA

Select another date: